- Home
- LEGH vs MLYS Comparison
LEGH vs MLYS Comparison
Compare LEGH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGH | MLYS |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 480.0M | 3.1B |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LEGH | MLYS |
|---|---|---|
| Price | $20.61 | $38.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $25.00 | ★ $46.40 |
| AVG Volume (30 Days) | 126.6K | ★ 1.7M |
| Earning Date | 11-07-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $180,497,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.07 | N/A |
| P/E Ratio | $10.45 | ★ N/A |
| Revenue Growth | ★ 10.25 | N/A |
| 52 Week Low | $18.84 | $8.24 |
| 52 Week High | $29.45 | $47.65 |
Technical Indicators
Market Signals| Indicator | LEGH | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 49.95 | 45.56 |
| Support Level | $19.35 | $35.77 |
| Resistance Level | $20.91 | $44.13 |
| Average True Range (ATR) | 0.68 | 1.93 |
| MACD | 0.26 | -0.55 |
| Stochastic Oscillator | 83.13 | 32.18 |
Price Performance
Historical ComparisonAbout LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.